China's Innovative Drug Licensing Deals Flourish at Import Expo, Highlighted by Multinational Pharma

2026-11-09 11:10 · source: ThePaper.cn · lang: zh-TW

The recent China International Import Expo (CIIE) has once again served as a major showcase for the rapid advancements and global integration of China’s pharmaceutical sector. A prominent trend at this year’s exhibition was the surge in business development (BD) activities involving Chinese innovative drugs, with numerous multinational pharmaceutical giants proudly displaying new milestones in cross-border collaboration and licensing agreements.

Industry observers noted that the focus has shifted from merely introducing foreign medical devices to the Chinese market to actively co-developing homegrown therapies. Global pharmaceutical leaders emphasized their long-term confidence in the Chinese market, citing the rich pipeline of domestic clinical innovations and supportive regulatory reforms. Companies highlighted their ongoing efforts to strengthen local supply chains, foster R&D partnerships, and integrate Chinese clinical expertise into global drug development strategies.

The bustling activity at the expo reflects China’s transition from a regional market to a crucial engine of global pharmaceutical innovation. By combining local clinical research capabilities with international commercial networks, domestic biotech firms and global giants are accelerating the delivery of novel treatments to patients worldwide, signaling a new era of mutually beneficial cooperation in the healthcare industry.

Sources: The Paper, Chinanews, Observer Net, Shanghai Hotline, Sohu